Despite the dismal economic climate, biotech stocks, financing, acquisitions and partnerships remained relatively solid. Although biotech indices have climbed only slightly since the beginning of 3Q07, they have performed much better than the broader indices, which plunged. Large bids to acquire Genentech (S. San Francisco, CA, USA) and ImClone (New York) also generated interest in the sector. Financing is unlikely to outstrip the $53 billion high in 2007, but last quarter actually managed to improve over a recent low in 2Q08.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lawrence, S. Biotech resilient in Q3. Nat Biotechnol 26, 1212 (2008). https://doi.org/10.1038/nbt1108-1212
Issue Date:
DOI: https://doi.org/10.1038/nbt1108-1212
This article is cited by
-
Venture capital shifts strategies, startups suffer
Nature Biotechnology (2009)